RG 3487

Drug Profile

RG 3487

Alternative Names: MEM3454; R1589; R3487; RG3487; RO5313534

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memory Pharmaceuticals; Roche
  • Developer Roche
  • Class Antidementias; Antipsychotics; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Schizophrenia
  • Discontinued Alzheimer's disease

Most Recent Events

  • 13 Nov 2010 Preclinical pharmacodynamics data presented at the 40th Annual Meeting of the Society for Neuroscience (SFN-2010)
  • 21 Oct 2009 Pharmacodynamics & pharmacokinetics data from preclinical trials in Alzheimer's disease presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
  • 24 Dec 2008 Memory initiates enrolment in a phase II trial for Schizophrenia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top